When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

Bone Marrow Transplant. 2017 Oct;52(10):1448-1451. doi: 10.1038/bmt.2017.109. Epub 2017 Jun 5.

Authors

C Solano^{1

2}, E Giménez³, J L Piñana¹, J C Hernández-Boluda¹, P Amat¹, V Vinuesa³, D Navarro^{3

4}

Affiliations

¹ Hematology Service, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia, Spain.
² Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
³ Microbiology Service, Hospital Clínico Universitario, Institute for Research INCLIVA, Valencia, Spain.
⁴ Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain.

PMID: 28581458
DOI: 10.1038/bmt.2017.109

No abstract available

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Allografts
Cytomegalovirus Infections / drug therapy*
Cytomegalovirus*
Female
Hematologic Neoplasms / therapy*
Humans
Male
Middle Aged
Prospective Studies
Stem Cell Transplantation*